Adimab

Adimab is an industry leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, and translating target hypotheses into therapeutically relevant antibody drugs. Adimab has started more than 360 antibody discovery campaigns with more than eighty partners, which range from top academic institutions to top pharma companies.

The company focuses on developing human monoclonal and bispecific antibodies for oncology, immunomodulation, inflammation, neuroscience and pain. The Adimab platform is based on synthetic and natural immune repertoires, which are propagated and screened in its proprietary yeast system. Its technology allows selecting key antibody properties in real time.

Its primary discovery process has the goal of offering a diverse panel of fully human antibodies tailored to target product profile. The goal of primary discovery is to find the most diverse panel of leads to comprehensively interrogate the target biology people are hoping to modulate.